{"corpus_id":30789930,"paper_sha":"1739e6ce37dae0c5f2c8ccabdcc32dbb780591fb","doi":"10.1056/NEJM199302253280801","arxiv_id":null,"pmid":8381207,"pmcid":null,"mag_id":2338213273,"dblp_id":null,"acl_id":null,"title":"The emergence of drug-resistant tuberculosis in New York City.","year":1993,"publication_date":"1993-02-25","venue":"New England Journal of Medicine","journal":{"name":"The New England journal of medicine","pages":"\n          521-6\n        ","volume":"328 8"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":17,"citation_count":915,"influential_citation_count":25,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Acquired Immunodeficiency Syndrome","mj":false,"qs":[{"q":"complications","mj":false,"ui":"Q000150"}],"ui":"D000163"},{"d":"Adolescent","mj":false,"ui":"D000293"},{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Antitubercular Agents","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D000995"},{"d":"Centers for Disease Control and Prevention, U.S.","mj":false,"ui":"D002487"},{"d":"Drug Resistance, Microbial","mj":false,"ui":"D004352"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"HIV Infections","mj":false,"qs":[{"q":"complications","mj":false,"ui":"Q000150"}],"ui":"D015658"},{"d":"Health Surveys","mj":true,"ui":"D006306"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Isoniazid","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D007538"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Microbial Sensitivity Tests","mj":false,"ui":"D008826"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Mycobacterium tuberculosis","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"},{"q":"isolation & purification","mj":false,"ui":"Q000302"}],"ui":"D009169"},{"d":"New York City","mj":false,"qs":[{"q":"epidemiology","mj":false,"ui":"Q000453"}],"ui":"D009519"},{"d":"Rifampin","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D012293"},{"d":"Substance Abuse, Intravenous","mj":false,"qs":[{"q":"complications","mj":false,"ui":"Q000150"}],"ui":"D015819"},{"d":"Tuberculosis","mj":false,"qs":[{"q":"epidemiology","mj":true,"ui":"Q000453"},{"q":"mortality","mj":false,"ui":"Q000401"}],"ui":"D014376"},{"d":"Tuberculosis, Pulmonary","mj":false,"qs":[{"q":"epidemiology","mj":false,"ui":"Q000453"},{"q":"mortality","mj":false,"ui":"Q000401"}],"ui":"D014397"},{"d":"United States","mj":false,"ui":"D014481"}],"chemicals":[{"n":"Antitubercular Agents","ui":"D000995","reg":"0"},{"n":"Isoniazid","ui":"D007538","reg":"V83O1VOZ8L"},{"n":"Rifampin","ui":"D012293","reg":"VJT6J7R4TR"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJM199302253280801?articleTools=true","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/1739e6ce37dae0c5f2c8ccabdcc32dbb780591fb","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BACKGROUND: In the past decade the incidence of tuberculosis has increased nationwide and more than doubled in New York City, where there have been recent nosocomial outbreaks of multidrug-resistant tuberculosis. METHODS: We collected information on every patient in New York City with a positive culture for Mycobacterium tuberculosis during April 1991. Drug-susceptibility testing was performed at the Centers for Disease Control and Prevention. RESULTS: Of the 518 patients with positive cultures, 466 (90 percent) had isolates available for testing. Overall, 33 percent of these patients had isolates resistant to one or more antituberculosis drugs, 26 percent had isolates resistant to at least isoniazid, and 19 percent had isolates resistant to both isoniazid and rifampin. Of the 239 patients who had received antituberculosis therapy, 44 percent had isolates resistant to one or more drugs and 30 percent had isolates resistant to both isoniazid and rifampin. Among the patients who had never been treated, the proportion with resistance to one or more drugs increased from 10 percent in 1982 through 1984 to 23 percent in 1991 (P = 0.003). Patients who had never been treated and who were infected with the human immunodeficiency virus (HIV) or reported injection-drug use were more likely to have resistant isolates. Among patients with the acquired immunodeficiency syndrome, those with resistant isolates were more likely to die during follow-up through January 1992 (80 percent vs. 47 percent, P = 0.02). A history of antituberculosis therapy was the strongest predictor of the presence of resistant organisms (odds ratio, 2.7; P < 0.001). CONCLUSIONS: There has been a marked increase in drug-resistant tuberculosis in New York City. Previously treated patients, those infected with HIV, and injection-drug users are at increased risk for drug resistance. Measures to control and prevent drug-resistant tuberculosis are urgently needed.","claims":[{"public_id":"cl_a7484d00bf75392763e563a2fb9bde66","status":"active","text":"Among 466 New York City patients with Mycobacterium tuberculosis isolates tested from April 1991, 33 percent had resistance to one or more antituberculosis drugs, 26 percent had resistance to at least isoniazid, and 19 percent had resistance to both isoniazid and rifampin.","confidence":0.97,"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_a7484d00bf75392763e563a2fb9bde66"},{"public_id":"cl_e29e2491f5cd62c0dab9de4168927ba4","status":"active","text":"Among patients who had never been treated, resistance to one or more drugs increased from 10 percent in 1982 through 1984 to 23 percent in 1991.","confidence":0.94,"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_e29e2491f5cd62c0dab9de4168927ba4"},{"public_id":"cl_b8657fbdc4d24910f3ea0da6daac77f4","status":"active","text":"Among patients who had received antituberculosis therapy, 44 percent had isolates resistant to one or more drugs and 30 percent had isolates resistant to both isoniazid and rifampin.","confidence":0.96,"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_b8657fbdc4d24910f3ea0da6daac77f4"},{"public_id":"cl_8d881c0659d699d15e1474791ff107ff","status":"active","text":"Among patients with acquired immunodeficiency syndrome, resistant isolates were associated with higher mortality during follow-up through January 1992.","confidence":0.92,"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_8d881c0659d699d15e1474791ff107ff"},{"public_id":"cl_87e48113de0658dee820ccdf64167f40","status":"active","text":"Patients who had never been treated and who were infected with the human immunodeficiency virus or reported injection-drug use were more likely to have resistant isolates.","confidence":0.93,"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_87e48113de0658dee820ccdf64167f40"}],"concepts":[{"public_id":"co_17f10128abd6cbdbd4bb75089b7880c9","status":"active","name":"antituberculosis drugs","description":"Medications used to treat tuberculosis and assessed for isolate resistance in this paper.","types":["therapeutic agents"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_17f10128abd6cbdbd4bb75089b7880c9"},{"public_id":"co_287f26d2db5be78333d7c53395eaadc0","status":"active","name":"New York City","description":"The urban setting where the tuberculosis patients and drug-resistant cases were identified.","types":["location"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_287f26d2db5be78333d7c53395eaadc0"},{"public_id":"co_2ce012e05040abc69a2249755fceff51","status":"active","name":"resistant isolates","description":"Mycobacterium tuberculosis culture isolates showing resistance to one or more tested drugs.","types":["laboratory finding"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_2ce012e05040abc69a2249755fceff51"},{"public_id":"co_34b78f4d363e9c9a256cc799a5a3de75","status":"active","name":"isoniazid","description":"An antituberculosis drug used as a resistance endpoint in the susceptibility results.","types":["drug"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_34b78f4d363e9c9a256cc799a5a3de75"},{"public_id":"co_5281ee3812392fc29f7d848b40e780df","status":"active","name":"injection-drug use","description":"A reported patient behavior evaluated as a risk factor for resistant tuberculosis isolates.","types":["risk factor"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_5281ee3812392fc29f7d848b40e780df"},{"public_id":"co_5c2132240a6e1d9a015201777f192aeb","status":"active","name":"Mycobacterium tuberculosis","description":"The bacterial species cultured from patients and tested for drug susceptibility in this paper.","types":["organism"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_5c2132240a6e1d9a015201777f192aeb"},{"public_id":"co_77ea05908791919b9a95524509d853b2","status":"active","name":"drug-resistant tuberculosis","description":"Tuberculosis involving Mycobacterium tuberculosis isolates resistant to one or more antituberculosis drugs.","types":["condition"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_77ea05908791919b9a95524509d853b2"},{"public_id":"co_80d39e283dcd87500538e00fdf4ddcac","status":"active","name":"acquired immunodeficiency syndrome","description":"An HIV-related clinical condition used to compare mortality among patients with resistant and nonresistant isolates.","types":["condition"],"aliases":["AIDS"],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_80d39e283dcd87500538e00fdf4ddcac"},{"public_id":"co_825f1c14d6ddfd5aa8973d7cb1739872","status":"active","name":"rifampin","description":"An antituberculosis drug evaluated together with isoniazid for resistance in the susceptibility results.","types":["drug"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_825f1c14d6ddfd5aa8973d7cb1739872"},{"public_id":"co_9037f2dd02628f02919ce0fab9ac306a","status":"active","name":"human immunodeficiency virus","description":"A viral infection status considered as a risk factor for resistant tuberculosis isolates.","types":["virus"],"aliases":["HIV"],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_9037f2dd02628f02919ce0fab9ac306a"},{"public_id":"co_d2e387ae068548259a8ae9d6d17af2f2","status":"active","name":"multidrug-resistant tuberculosis","description":"Tuberculosis described in the abstract as resistant to multiple antituberculosis drugs during nosocomial outbreaks.","types":["condition"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_d2e387ae068548259a8ae9d6d17af2f2"},{"public_id":"co_e717de15c5bde3994e8de4e821ee5da5","status":"active","name":"antituberculosis therapy","description":"Prior treatment for tuberculosis recorded as a patient history variable in the analysis.","types":["treatment history"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_e717de15c5bde3994e8de4e821ee5da5"}],"external_ids":{"DOI":"10.1056/NEJM199302253280801","ArXiv":null,"PubMed":8381207,"PubMedCentral":null,"MAG":2338213273,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJM199302253280801?articleTools=true","landing_url":"https://www.semanticscholar.org/paper/1739e6ce37dae0c5f2c8ccabdcc32dbb780591fb","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632255,"paper_uid":"3a5c5ed4-54ae-4cee-8afa-409bdfdd1b36","canonical_identity":{"paper_id":632255,"paper_uid":"3a5c5ed4-54ae-4cee-8afa-409bdfdd1b36","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/30789930"}